Read all about it! The latest news from the medical technology experts
Revolutionising high eyePressure detection around Australia - and even in the Antarctic
Patents issued in key regions for the eyeTelehealth Platform
Patent issued for Ingeneus' eyeConnect device in China
Patents issued in the US and China for eyeTelehealth products
World first eyeConnect unveiled at Frankston Hospital
Ingeneus products - Good Design Awards winners
Ingeneus products in Good Design Awards finals
Ingeneus appoints new GM Manufacturing
Ingeneus launches eyePressure device
Ingeneus achieves CE Marking for ophthalmic system
Ingeneus develops new remote diagnostic tool
Ingeneus wins TGA and CE manufacturing approval for cataract surgery device
Medical device treats Ocular Pathologies during Vitreoretinal Surgery
V-Patch Medical Systems: reaching the hearts of the travelling public
Double Success for Ingeneus in Government Program
Ingeneus advocates change to the Therapeutic Goods Administration (TGA)
Ingeneus Exhibits at AusMedtech 2011 Conference
Dynamic enhancement of Ingeneus QMS for medical devices and biomedical applications
Exciting opportunities at BiOS 2011 for Ingeneus
Ingeneus engages with emerging markets
New branding & website under Design Vic Business Immersion program
Ingeneus completes software training with its clients
Ingeneus passes TGA Surveillance Audit
Ingeneus signs licensing agreement for low cost diabetic retinopathy system
News
Ingeneus achieves CE Marking for ophthalmic system
3rd September 2013
Ingeneus is pleased to announce that it has achieved CE Marking for its low cost treatment system for diabetic retinopathy, an eye disease that affects many diabetics. The system was developed by Ingeneus for use by ophthalmic clinicians.
CE Marking signifies that the product complies with the essential health, safety and environmental protection requirements of the European Medical Device Directive.
Ingeneus CEO Richard Walmsley said, “We are excited to receive the CE Mark as it means the system can be used by ophthalmic clinicians throughout Europe. It assures surgeons and patients of the safety and efficacy of our device.
The system provides clinicians with a complete laser solution in the treatment of ocular pathology and provides a new level of performance compared with existing surgery systems,” Richard said.
“It is used in photocoagulation of both anterior and posterior segments of the eye including retinal photocoagulation.”
